Annual EBITDA
-$78.09 M
-$39.23 M-100.94%
30 June 2024
Summary:
Renovaro Biosciences annual earnings before interest, taxes, depreciation & amortization is currently -$78.09 million, with the most recent change of -$39.23 million (-100.94%) on 30 June 2024. During the last 3 years, it has fallen by -$51.75 million (-196.42%). RENB annual EBITDA is now -261082.27% below its all-time high of -$29.90 thousand, reached on 01 March 2012.RENB EBITDA Chart
Add series to chart(max: 6)
company, ETF, index, featured screener or watchlist
Quarterly EBITDA
-$43.93 M
-$29.91 M-213.25%
30 September 2024
Summary:
Renovaro Biosciences quarterly earnings before interest, taxes, depreciation & amortization is currently -$43.93 million, with the most recent change of -$29.91 million (-213.25%) on 30 September 2024. Over the past year, it has dropped by -$39.71 million (-940.74%). RENB quarterly EBITDA is now -3697.84% below its all-time high of $1.22 million, reached on 01 June 2019.RENB Quarterly EBITDA Chart
Add series to chart(max: 6)
company, ETF, index, featured screener or watchlist
TTM EBITDA
-$113.04 M
-$34.96 M-44.78%
30 September 2024
Summary:
Renovaro Biosciences TTM earnings before interest, taxes, depreciation & amortization is currently -$113.04 million, with the most recent change of -$34.96 million (-44.78%) on 30 September 2024. Over the past year, it has dropped by -$72.91 million (-181.66%).RENB TTM EBITDA Chart
Add series to chart(max: 6)
company, ETF, index, featured screener or watchlist
RENB EBITDA Performance
| PeriodPeriod | AnnualAnnual | QuarterlyQuarterly | TTMTTM |
|---|---|---|---|
| 1 y1 year | -100.9% | -940.7% | -181.7% |
| 3 y3 years | -196.4% | -580.3% | -198.4% |
| 5 y5 years | -335.2% | -2497.4% | -1912.3% |
RENB EBITDA High & Low
| PeriodPeriod | Annual vs highAnnual vs high | Annual vs lowAnnual vs low | Quarter. vs highQuarter. vs high | Quarter. vs lowQuarter. vs low | TTM vs highTTM vs high | TTM vs lowTTM vs low | |
|---|---|---|---|---|---|---|---|
| 3 y | 3 years | -196.4% | +30.9% | -988.7% | +51.3% | -198.4% | at low |
| 5 y | 5 years | -613.5% | +30.9% | -2895.1% | +51.3% | -2493.8% | at low |
| alltime | all time | <-9999.0% | +30.9% | -3697.8% | +51.3% | <-9999.0% | at low |
Renovaro Biosciences EBITDA History
| Date | Annual | Quarterly | TTM |
|---|---|---|---|
| Sept 2024 | - | -$43.93 M(+213.3%) | -$113.04 M(+44.8%) |
| June 2024 | -$78.09 M(+100.9%) | -$14.02 M(-72.4%) | -$78.08 M(-10.2%) |
| Mar 2024 | - | -$50.86 M(+1105.0%) | -$86.96 M(+116.7%) |
| Dec 2023 | - | -$4.22 M(-52.9%) | -$40.13 M(-0.3%) |
| Sept 2023 | - | -$8.97 M(-60.8%) | -$40.25 M(+3.6%) |
| June 2023 | -$38.86 M(-65.6%) | - | - |
| June 2023 | - | -$22.91 M(+467.7%) | -$38.85 M(-63.4%) |
| Mar 2023 | - | -$4.04 M(-6.9%) | -$106.06 M(-1.9%) |
| Dec 2022 | - | -$4.34 M(-42.8%) | -$108.10 M(-1.9%) |
| Sept 2022 | - | -$7.58 M(-91.6%) | -$110.22 M(-2.4%) |
| June 2022 | -$112.94 M(+328.7%) | -$90.11 M(+1383.5%) | -$112.94 M(+181.9%) |
| Mar 2022 | - | -$6.07 M(-5.9%) | -$40.06 M(+5.7%) |
| Dec 2021 | - | -$6.46 M(-37.2%) | -$37.89 M(+10.7%) |
| Sept 2021 | - | -$10.29 M(-40.3%) | -$34.24 M(+30.0%) |
| June 2021 | -$26.35 M(+140.7%) | -$17.23 M(+341.4%) | -$26.35 M(+105.3%) |
| Mar 2021 | - | -$3.90 M(+38.9%) | -$12.83 M(+23.5%) |
| Dec 2020 | - | -$2.81 M(+17.3%) | -$10.39 M(+12.1%) |
| Sept 2020 | - | -$2.40 M(-35.6%) | -$9.27 M(-0.3%) |
| June 2020 | -$10.95 M(-39.0%) | -$3.72 M(+153.5%) | -$9.30 M(+113.3%) |
| Mar 2020 | - | -$1.47 M(-13.3%) | -$4.36 M(-22.4%) |
| Dec 2019 | - | -$1.69 M(-30.1%) | -$5.62 M(-71.9%) |
| Sept 2019 | - | -$2.42 M(-298.3%) | -$20.02 M(+3.2%) |
| June 2019 | -$17.94 M(+186.6%) | $1.22 M(-144.8%) | -$19.41 M(-13.8%) |
| Mar 2019 | - | -$2.73 M(-83.1%) | -$22.51 M(+1.1%) |
| Dec 2018 | - | -$16.09 M(+790.5%) | -$22.26 M(+207.9%) |
| Sept 2018 | - | -$1.81 M(-4.1%) | -$7.23 M(+28.0%) |
| June 2018 | -$6.26 M | -$1.89 M(-23.9%) | -$5.65 M(+43.6%) |
| Date | Annual | Quarterly | TTM |
|---|---|---|---|
| Mar 2018 | - | -$2.48 M(+133.3%) | -$3.93 M(+130.4%) |
| Dec 2017 | - | -$1.06 M(+370.5%) | -$1.71 M(+8.9%) |
| Sept 2017 | - | -$225.70 K(+33.6%) | -$1.57 M(-27.7%) |
| June 2017 | -$2.17 M(-0.1%) | -$168.90 K(-32.6%) | -$2.17 M(-22.9%) |
| Mar 2017 | - | -$250.70 K(-72.8%) | -$2.81 M(+0.5%) |
| Dec 2016 | - | -$921.90 K(+11.7%) | -$2.80 M(+6.7%) |
| Sept 2016 | - | -$825.50 K(+1.4%) | -$2.62 M(+21.0%) |
| June 2016 | -$2.17 M(-20.1%) | -$813.90 K(+243.3%) | -$2.17 M(+60.2%) |
| Mar 2016 | - | -$237.10 K(-68.2%) | -$1.35 M(-42.3%) |
| Dec 2015 | - | -$745.30 K(+101.6%) | -$2.34 M(-8.3%) |
| Sept 2015 | - | -$369.70 K(-69.9%) | -$2.55 M(-21.2%) |
| June 2015 | -$2.71 M(+12.1%) | - | - |
| Mar 2015 | - | -$1.23 M(+28.0%) | -$3.24 M(+33.9%) |
| Dec 2014 | -$2.42 M(+6419.4%) | -$958.00 K(+94.7%) | -$2.42 M(+64.6%) |
| Sept 2014 | - | -$492.10 K(-12.9%) | -$1.47 M(+47.9%) |
| June 2014 | - | -$564.70 K(+39.3%) | -$994.10 K(+130.2%) |
| Mar 2014 | - | -$405.30 K(+4903.7%) | -$431.90 K(+1099.7%) |
| Dec 2013 | - | -$8100.00(-49.4%) | -$36.00 K(-4.0%) |
| Sept 2013 | - | -$16.00 K(+540.0%) | -$37.50 K(+31.6%) |
| June 2013 | - | -$2500.00(-73.4%) | -$28.50 K(-23.0%) |
| Mar 2013 | -$37.10 K(+24.1%) | -$9400.00(-2.1%) | -$37.00 K(+15.6%) |
| Dec 2012 | - | -$9600.00(+37.1%) | -$32.00 K(-5.3%) |
| Sept 2012 | - | -$7000.00(-36.4%) | -$33.80 K(-17.6%) |
| June 2012 | - | -$11.00 K(+150.0%) | -$41.00 K(+36.7%) |
| Mar 2012 | -$29.90 K(-12.8%) | -$4400.00(-61.4%) | -$30.00 K(+17.2%) |
| Dec 2011 | -$34.30 K | -$11.40 K(-19.7%) | -$25.60 K(+80.3%) |
| Sept 2011 | - | -$14.20 K(<-9900.0%) | -$14.20 K(<-9900.0%) |
| June 2011 | - | $0.00 | $0.00 |
FAQ
- What is Renovaro Biosciences annual earnings before interest, taxes, depreciation & amortization?
- What is the all time high annual EBITDA for Renovaro Biosciences?
- What is Renovaro Biosciences annual EBITDA year-on-year change?
- What is Renovaro Biosciences quarterly earnings before interest, taxes, depreciation & amortization?
- What is the all time high quarterly EBITDA for Renovaro Biosciences?
- What is Renovaro Biosciences quarterly EBITDA year-on-year change?
- What is Renovaro Biosciences TTM earnings before interest, taxes, depreciation & amortization?
- What is the all time high TTM EBITDA for Renovaro Biosciences?
- What is Renovaro Biosciences TTM EBITDA year-on-year change?
What is Renovaro Biosciences annual earnings before interest, taxes, depreciation & amortization?
The current annual EBITDA of RENB is -$78.09 M
What is the all time high annual EBITDA for Renovaro Biosciences?
Renovaro Biosciences all-time high annual earnings before interest, taxes, depreciation & amortization is -$29.90 K
What is Renovaro Biosciences annual EBITDA year-on-year change?
Over the past year, RENB annual earnings before interest, taxes, depreciation & amortization has changed by -$39.23 M (-100.94%)
What is Renovaro Biosciences quarterly earnings before interest, taxes, depreciation & amortization?
The current quarterly EBITDA of RENB is -$43.93 M
What is the all time high quarterly EBITDA for Renovaro Biosciences?
Renovaro Biosciences all-time high quarterly earnings before interest, taxes, depreciation & amortization is $1.22 M
What is Renovaro Biosciences quarterly EBITDA year-on-year change?
Over the past year, RENB quarterly earnings before interest, taxes, depreciation & amortization has changed by -$39.71 M (-940.74%)
What is Renovaro Biosciences TTM earnings before interest, taxes, depreciation & amortization?
The current TTM EBITDA of RENB is -$113.04 M
What is the all time high TTM EBITDA for Renovaro Biosciences?
Renovaro Biosciences all-time high TTM earnings before interest, taxes, depreciation & amortization is $0.00
What is Renovaro Biosciences TTM EBITDA year-on-year change?
Over the past year, RENB TTM earnings before interest, taxes, depreciation & amortization has changed by -$72.91 M (-181.66%)